letrozole

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

Aromatase inhibitor

Related drugs:

‹

›

No biomarker	Breast Cancer	No biomarker	Breast Cancer	letrozole Sensitive: A1 - Approval letrozole Sensitive : A1	letrozole Sensitive: A1 - Approval letrozole Sensitive : A1
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	letrozole Sensitive: A1 - Approval letrozole Sensitive : A1	letrozole Sensitive: A1 - Approval letrozole Sensitive : A1
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	fulvestrant + letrozole Sensitive: A2 - Guideline fulvestrant + letrozole Sensitive : A2	fulvestrant + letrozole Sensitive: A2 - Guideline fulvestrant + letrozole Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2
PGR positive	HER2 Negative Breast Cancer	PGR positive	HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	everolimus + letrozole Sensitive: A2 - Guideline everolimus + letrozole Sensitive : A2	everolimus + letrozole Sensitive: A2 - Guideline everolimus + letrozole Sensitive : A2
No biomarker	Ovarian Serous Adenocarcinoma	No biomarker	Ovarian Serous Adenocarcinoma	carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive : A2	carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive : A2	carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Ovarian Serous Adenocarcinoma	No biomarker	Ovarian Serous Adenocarcinoma	carboplatin + docetaxel + letrozole Sensitive: A2 - Guideline carboplatin + docetaxel + letrozole Sensitive : A2	carboplatin + docetaxel + letrozole Sensitive: A2 - Guideline carboplatin + docetaxel + letrozole Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	carboplatin + docetaxel + letrozole Sensitive: A2 - Guideline carboplatin + docetaxel + letrozole Sensitive : A2	carboplatin + docetaxel + letrozole Sensitive: A2 - Guideline carboplatin + docetaxel + letrozole Sensitive : A2
FGFR1 amplification	Hormone Receptor Positive Breast Cancer	FGFR1 amplification	Hormone Receptor Positive Breast Cancer	letrozole Resistant: B - Late Trials letrozole Resistant : B	letrozole Resistant: B - Late Trials letrozole Resistant : B
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	letrozole Sensitive: C2 – Inclusion Criteria letrozole Sensitive : C2	letrozole Sensitive: C2 – Inclusion Criteria letrozole Sensitive : C2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	everolimus + letrozole + leuprolide acetate Sensitive: C3 – Early Trials everolimus + letrozole + leuprolide acetate Sensitive : C3	everolimus + letrozole + leuprolide acetate Sensitive: C3 – Early Trials everolimus + letrozole + leuprolide acetate Sensitive : C3
ER positive	Endometrial Cancer	ER positive	Endometrial Cancer	palbociclib + letrozole Sensitive: C3 – Early Trials palbociclib + letrozole Sensitive : C3	palbociclib + letrozole Sensitive: C3 – Early Trials palbociclib + letrozole Sensitive : C3
PIK3CA mutation	Estrogen Receptor Positive Breast Cancer	PIK3CA mutation	Estrogen Receptor Positive Breast Cancer	letrozole Sensitive: C3 – Early Trials letrozole Sensitive : C3	letrozole Sensitive: C3 – Early Trials letrozole Sensitive : C3
CTNNB1 mutation	Endometrial Cancer	CTNNB1 mutation	Endometrial Cancer	everolimus + letrozole Sensitive: C3 – Early Trials everolimus + letrozole Sensitive : C3	everolimus + letrozole Sensitive: C3 – Early Trials everolimus + letrozole Sensitive : C3
ER positive + PGR positive	HER2 Negative Breast Cancer	ER positive + PGR positive	HER2 Negative Breast Cancer	letrozole Sensitive: C3 – Early Trials letrozole Sensitive : C3	letrozole Sensitive: C3 – Early Trials letrozole Sensitive : C3
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pyrotinib + letrozole Sensitive: C3 – Early Trials pyrotinib + letrozole Sensitive : C3	pyrotinib + letrozole Sensitive: C3 – Early Trials pyrotinib + letrozole Sensitive : C3
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	pyrotinib + letrozole Sensitive: C3 – Early Trials pyrotinib + letrozole Sensitive : C3	pyrotinib + letrozole Sensitive: C3 – Early Trials pyrotinib + letrozole Sensitive : C3
miR-125b-2 expression	HER2 Positive Breast Cancer	miR-125b-2 expression	HER2 Positive Breast Cancer	letrozole Resistant: C3 – Early Trials letrozole Resistant : C3	letrozole Resistant: C3 – Early Trials letrozole Resistant : C3
miR-155 expression	HER2 Positive Breast Cancer	miR-155 expression	HER2 Positive Breast Cancer	letrozole Resistant: C3 – Early Trials letrozole Resistant : C3	letrozole Resistant: C3 – Early Trials letrozole Resistant : C3
miR-221 underexpression	HER2 Positive Breast Cancer	miR-221 underexpression	HER2 Positive Breast Cancer	letrozole Sensitive: C3 – Early Trials letrozole Sensitive : C3	letrozole Sensitive: C3 – Early Trials letrozole Sensitive : C3
miR-125b-2 underexpression	HER2 Positive Breast Cancer	miR-125b-2 underexpression	HER2 Positive Breast Cancer	letrozole Sensitive: C3 – Early Trials letrozole Sensitive : C3	letrozole Sensitive: C3 – Early Trials letrozole Sensitive : C3
miR-221 expression	HER2 Positive Breast Cancer	miR-221 expression	HER2 Positive Breast Cancer	letrozole Resistant: C3 – Early Trials letrozole Resistant : C3	letrozole Resistant: C3 – Early Trials letrozole Resistant : C3
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	letrozole + SAR439859 Sensitive: C3 – Early Trials letrozole + SAR439859 Sensitive : C3	letrozole + SAR439859 Sensitive: C3 – Early Trials letrozole + SAR439859 Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	letrozole + dalpiciclib Sensitive: C3 – Early Trials letrozole + dalpiciclib Sensitive : C3	letrozole + dalpiciclib Sensitive: C3 – Early Trials letrozole + dalpiciclib Sensitive : C3
ER positive + PGR negative	HER2 Negative Breast Cancer	ER positive + PGR negative	HER2 Negative Breast Cancer	letrozole Sensitive: C4 – Case Studies letrozole Sensitive : C4	letrozole Sensitive: C4 – Case Studies letrozole Sensitive : C4

letrozole

Associations
(36)

Associations
(36)

letrozole

Associations(36)

Associations(36)

Associations
(36)

Associations
(36)